BMS, AZ pull Forxiga in Germany

Bristol-Myers Squibb Co. (NYSE:BMY) and AstraZeneca plc (LSE:AZN; NYSE:AZN) are pulling Type II diabetes drug Forxiga dapagliflozin off the market in Germany after failing to agree on a price with Germany's Statutory Health Insurance Funds Association (GKV-Spitzenverband). The partners said they may reexamine the move after a price for Forxiga is determined through independent arbitration, which is expected in 1Q14. In June, Germany's Federal Joint Committee (G-BA) said in a final benefit assessment that Forxiga has "no additional benefit" vs. four sets of requested comparators. The European Commission approved the drug in November 2012 (see BioCentury Extra, June 6). ...